AstraZeneca : Remuneration Committee Chair Appointment - Form 6-K

Remuneration Committee Chair Appointment

AstraZeneca PLC today announced the appointment of Sheri McCoy, Non-Executive Director, as Chair of the Remuneration Committee. Sheri has served as a member of the Remuneration Committee since July 2018.

Sheri will succeed Michel Demaré who will step down as Chair of the Remuneration Committee following his recent appointment as Chair-designate of the Board. He will remain a member of the Committee.

Sheri will also become a member of the Nomination and Governance Committee.

These Remuneration Committee and Nomination and Governance Committee changes are effective from 1 December 2022. As previously announced, Michel Demaré will become Chair of the Board at the end of the Company's Annual General Meeting in April 2023.

Notes

Biography and photograph:

https://www.astrazeneca.com/our-company/leadership.html#board

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp

Company Secretary

AstraZeneca PLC